TWEAK as a target for therapy in systemic lupus erythematosus

Mol Biol Rep. 2011 Jan;38(1):587-92. doi: 10.1007/s11033-010-0144-9. Epub 2010 Apr 1.

Abstract

Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) is a recently identified proinflammatory cytokine of the TNF superfamily. Through activation of the fibroblast growth factor-inducible 14 (Fn14) receptor, TWEAK regulates cell proliferation, cell death and inflammation. The available evidences have indicated that TWEAK might be a target for therapeutic intervention in renal, vascular injury and neuropathy. Since renal, vascular and neuropsychiatric complications are frequently encountered in systemic lupus erythematosus (SLE)--a systemic autoimmune disease, TWEAK-Fn14 pathway may be implicated in the pathogenesis of SLE. In this review, we will discuss the TWEAK-Fn14 pathway and the therapeutic potential of modulating this pathway in SLE.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cytokine TWEAK
  • Humans
  • Lupus Erythematosus, Systemic / etiology
  • Lupus Erythematosus, Systemic / pathology
  • Lupus Erythematosus, Systemic / therapy*
  • Receptors, Tumor Necrosis Factor / metabolism*
  • TWEAK Receptor
  • Tumor Necrosis Factors / metabolism*

Substances

  • Cytokine TWEAK
  • Receptors, Tumor Necrosis Factor
  • TNFRSF12A protein, human
  • TNFSF12 protein, human
  • TWEAK Receptor
  • Tumor Necrosis Factors